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Abstract 
The notorious unresponsiveness of metastatic cutaneous melanoma to current treatment strategies 
coupled with its increasing incidence constitutes a serious worldwide clinical problem. Moreover, 
despite recent advances in targeted therapies for patients with BRAFV600E mutant melanomas, 
acquired resistance remains a limiting factor and hence emphasises the acute need for 
comprehensive pre-clinical studies to increase the biological understanding of such tumours in order 
to develop novel effective and long lasting therapeutic strategies. Autophagy and ER stress both 
play a role in melanoma development/progression and chemoresistance although their real impact is 
still unclear. Here we show that BRAFV600E induces a chronic ER stress status directly increasing 
basal cell autophagy. BRAFV600E-mediated p38 activation stimulates both the IRE1/ASK1/JNK and 
TRB3 pathways. Bcl-XL/Bcl-2 phosphorylation by active JNK releases Beclin1 while TRB3 
inhibits the Akt/mTor axes, together resulting in an increase in basal autophagy. Furthermore, we 
demonstrate chemical chaperones relieve the BRAFV600E-mediated chronic ER stress status, 
consequently reducing basal autophagic activity and increasing, the sensitivity of melanoma cells to 
apoptosis. Taken together, these results suggest enhanced basal autophagy, typically observed in  
BRAFV600E melanomas, is a consequence of a chronic ER stress status, which ultimately results in 
the chemoresistance of such tumours. Targeted therapies which attenuate ER stress may therefore 
represent a novel and more effective therapeutic strategy for BRAF mutant melanoma. 
 
Keywords: Autophagy; BRAF; Chemical Chaperones; ER stress; Melanoma 
Abbreviations: ER = Endoplasmic Reticulum; UPR = Unfolded Protein Response; Baf  = 
Bafilomycin A; wt = wild-type; DN = Dominant Negative; 4-PBA = 4-Phenylbutyric acid; TG = 
thapsigargin; STS = staurosporine; DoxR = doxorubicine. 
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Introduction 
Cutaneous melanoma represents one of the most aggressive and difficult to treat forms of human 
cancer, with a worldwide incidence that has steadily increased over the past 40 years 1,2. 
Notoriously unresponsive to conventional chemotherapy, metastatic disease is highly invasive and 
evolves with an extensive repertoire of molecular defences against immunological and cytotoxic 
attack 3. 
Although linked to exposure to ultraviolet light, it is widely accepted that both genotypic and 
phenotypic changes in melanocytes predispose to melanocyte transformation and the onset of 
melanoma 4,5.  
Surprisingly, p53 mutations are very rare in melanoma, but activity is however, impaired through 
direct or indirect inactivation of key elements of this pathway, including through the suppression of 
APAF-1 expression 6, loss of PTEN function 7, dysregulation of Bcl-2 expression 8, up-regulation of 
the anti-apoptotic protein Mcl-1 together with its altered slice variant expression 9,10 and the ER 
chaperone GRP78 11-13. Oncogenic mutations however, in the Ras/Raf pathway are the most well 
described  genetic mutations associated with melanoma development and progression 14. Indeed, up 
to 90% of all melanomas harbour activating NRAS or BRAF mutations, with BRAFV600E 
representing more than 90% of BRAF mutations 15,16, the consequence of which is the constitutive 
activation of RAF-extracellular signal-regulated kinase/ERK signalling promoting melanoma 
proliferation and resistance to apoptosis 17. Nevertheless, mutation of NRAS/BRAF alone is not 
sufficient to initiate melanomagenesis, since these common mutations are also present in benign 
nevi, thereby highlighting the requirement of other factors to drive melanocyte transformation and 
melanoma development 15,16. Dysregulation of autophagy has accordingly been postulated as a 
secondary event contributing to melanoma progression and, importantly, also plays a key role in 
chemoresistance 18-20. 
Autophagy is the principle catabolic process for the bulk degradation and recycling of 
aged/damaged cellular components, organelles and proteins through the formation of a double 
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membraned cytosolic vesicle able to wrap targeted material. The subsequent fusion with lysosomes 
and degradation of cargo provide nutrients in times of environmental stress, such as nutrient 
deprivation or hypoxia 21. Though essential for the maintenance of cellular homeostasis under 
conditions of nutrient deprivation, paradoxically, autophagy promotes both tumour suppression and 
tumour development 22. While the accumulation of damaged organelles/cytosolic proteins may lead 
to cellular transformation, autophagy may also sustain tumour growth in a microenvironment which 
is commonly poor of oxygen and nutrients 22. Thus not surprisingly, autophagy activation is 
frequently observed in late stage malignancy although the molecular mechanisms mediating its 
activation/regain of function remain unclear. 
ER stress, may also constitute a key secondary event in melanoma development 23. Primarily a 
cytoprotective pro-survival process, ER stress is activated as a result of accumulated unfolded 
proteins, protein overload or depletion of ER calcium stores and mediated through the activity of 
the master ER chaperone Grp78 and three signalling pathways; PERK/eIF2α/ATF4, IRE-1/Xbp-1 
and ATF6 which collectively maintain ER homeostasis through the instigation of an Unfolded 
Protein Response (UPR) 24 or sustained ER stress may lead to the induction of  apoptosis 25,26. 
Increasing evidence indicates nutrient deprivation and hypoxia lead to activation of the UPR in 
various solid tumours, frequently correlating with resistance to chemotherapy 27. The accepted 
hypothesis is thus that activation of the UPR in cancer cells enables their adaption to such ER stress 
resulting in the resistance to apoptosis through the persistent expression of pro-survival instead of 
pro-apoptotic proteins 28. 
Although under stress conditions, autophagy and ER stress seem to act in parallel, indeed they are 
closely related, since one can regulate the other and vice versa. In fact, ER stress is able to promptly 
stimulate autophagy26, whereas autophagy selectively removes the membranes of the endoplasmic 
reticulum at the end of the UPR, although the molecular mechanisms are still largely unclear29. 
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In the present study we investigated the link between oncogenic BRAFV600E and increased basal 
autophagy in melanoma cells, highlighting the pivotal role played by ER stress, possibly 
responsible for tumour growth and chemoresistance.   
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Results 
 
BRAFV600E increases basal autophagy in melanoma cells 
The deregulation of autophagy is frequent in malignancy, including in cutaneous melanomas. In 
particular, we and others have recently demonstrated melanomas harbouring mutant BRAFV600E, 
display an increased basal autophagic rate 3,20,30,31. In order to confirm this observation we 
compared basal autophagic flux in melanoma cell lines, CHL-1 and A375, with BRAF wild-type 
(wt) or V600E mutated alleles, respectively. As shown in figure 1A, A375 cells displayed increased 
expression of lipidated LC3 compared to CHL-1 cells, which was sustained by co-treatment with 
Bafilomycin A (Baf), to prevent autophagic flux. To further confirm these observations, analysis of 
LC3 conversion was also performed in an extended panel of BRAF wt or mutated melanoma cells 
(Supplementary Table 1, Figure 1C). Results confirmed an overall increase in basal autophagy in 
BRAF mutant compared to BRAF wt cells (Figure 1C). Moreover, increased basal degradation of 
the autophagy cargo p62 was also observed in A375 compared to CHL-1 cells, as evidenced by the 
accumulation of this protein in presence of Baf (Fig 1B), and confirmed comparing p62 
accumulation in BRAF mutated vs BRAF wt melanoma cell lines, in a time-dependent manner (Fig 
1D). 
Since autophagy is primarily a pro-survival pathway actively counteracting the apoptotic process, 
high basal autophagy levels may account for, at least in part, the notorious resistance of BRAF 
mutated melanoma cells to ER stress-induced apoptosis 17, as confirmed in figure 1E also showing 
A375 cells are more resistant to thapsigargin-induced apoptosis, compared to CHL-1 cells. 
 
Oncogenic BRAF results in increased basal autophagy through chronic ER stress induction  
We have previously shown that BRAF mutated melanoma cells display reduced sensitivity to ER 
stress activation compared to wt cells, suggesting that an abrogated ER stress response may limit 
drug-induced apoptosis in these cells 20,32 (Fig 1). We therefore hypothesised that the reduced ER 
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stress response observed in BRAF mutant melanoma cells results from chronic ER stress that 
desensitizes them to further stress stimuli 28. To test this hypothesis we analysed the expression 
levels of ER stress markers in our extended panel of BRAFV600E melanoma cells compared to 
BRAFWT cells. As shown in figure 2A, BRAFV600E melanoma cell lines displayed approximately 
two fold greater expression of mRNA coding for ERdj5, ERp57, ATF4 and Xbp-I 33, compared to 
BRAF wt cells, indicating that a mild but consistent induction of ER stress is conferred by an 
activating mutation in the BRAF protein kinase. 28,32,33. 
To rule out the possibility that differences in ER stress induction were due to effects other than 
BRAF mutation, we expressed constitutively active BRAFV600E in the BRAF wt SK-Mel-110 
melanoma cell line in order to compare melanoma cells with identical genetic background except 
for BRAF status. Cells stably expressing BRAFV600E or GFP were selected for more than one month 
in culture, in order to better represent in vivo tumour development and adaptation to BRAF 
activating mutation. Expression of oncogenic BRAF in SK-Mel-110 cells, as evidenced by ERK1/2 
hyper-phosphorylation (Fig 2C), resulted in a clear up-regulation of mRNA coding for ERp57, 
ATF4, ERdj5 and Xbp-I (Fig 2B), increased levels of both calnexin and ERp57 proteins and eIF2α 
phosphorylation (Fig 2D), as well as enhanced Xbp-I splicing (Fig 2E), confirming BRAF mutation 
is solely responsible for ER compartment deregulation, and compatible with a chronic ER stress 
status. These data thus support recent observations of increased ER stress as a consequence of 
BRAF therapy-induced resistance by Ma and co-workers34, and provide additional insight into the 
mechanisms mediating increased basal ER stress in BRAF mutated melanoma cells. 
Furthermore, over-expression of BRAFV600E also resulted in increased basal autophagy in SK-Mel-
110 cells, as indicated by both the cytosolic accumulation of p62 puncta (Fig 3A) and LC3 
conversion (Fig 3B), in a time-dependent manner and under conditions of bafilomycin exposure, 
suggesting a correlation between chronic ER stress and increased basal autophagy in BRAFV600E 
mutant cells, as previously evidenced in Figure 1. 
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ER stress-mediated JNK activation contributes to basal autophagy induction 
To unveil the possible link connecting oncogenic BRAF-induced chronic ER stress and the 
elevation of basal autophagy, we explored the activation of known pathways linking these two 
processes. Results demonstrated constitutive phosphorylation of JNK in BRAFV600E compared to 
BRAF wt cells and normal melanocytes, confirming protein kinase activation (Fig 4A). To verify 
JNK activation was specifically due to the presence of oncogenic BRAF, we analysed JNK 
phosphorylation in SK-Mel-110 cells stably expressing BRAFV600E or GFP. As shown in figure 4C, 
phosphorylated JNK is strictly associated with the expression of mutant BRAF. 
ER stress-mediated JNK activation has also been reported to be associated with the activation of the 
transmembrane ER protein IRE1 and subsequent recruitment of cytosolic ASK1 through the adapter 
molecule TRAF2 35. This multiprotein complex determines the activation of the kinase ASK1, thus 
mediating the phosphorylation of JNK 35. To verify the involvement of this pathway in oncogenic 
BRAF-induced ER stress-mediated JNK activation, we evaluated the translocation of TRAF2 onto 
ER membranes using a subcellular fractionation assay. Results reported in figure 4B and 4D 
confirmed a mild but significant relocalization of TRAF2 onto the ER compartment, as indicated by 
the colocalization with the ER marker calnexin, in cells expressing the mutated BRAF (see arrows 
in Fig 4B and 4D, compare each upper panel with corresponding bottom panel), consistent with a 
chronic rather than an acute ER stress status. Importantly, this relocalization was specifically 
induced by BRAFV600E since GFP-transduced SK-Mel-110 cells exhibited TRAF2 distribution 
similar to that observed in CHL-1 cells (see arrows as marked in Fig 4D and 4B, upper panels). This 
evidence was further confirmed by evaluating the relocalization of TRAF2 onto ER membranes of 
other BRAF mutated cell lines compared to BRAF wt once (Supplementary Figure S1).  
To confirm the role of the IRE-1/TRAF2/ASK1 axes in the JNK activation and autophagy induction 
in BRAFV600E cells, we down-regulated the expression of IRE1 using two specific shRNA’s  in 
A375 cells (Fig 4E, left panel) and evaluated the level of both phosphorylated JNK and LC3 
conversion. As shown in figure 4E, the impairment of the IRE1 signalling pathway resulted in 
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decreased JNK activation (upper right panel) and concomitant reduction of A375 basal autophagy 
(bottom right panel). To further confirm these results, A375 cells were treated with SP600125 (10 
μM) to inhibit JNK activation 36 prior to analysing of basal autophagic activity, in presence or 
absence of bafilomycin. As shown in figure 5 A-D, inhibiting the activation of JNK resulted in a 
clear decrease in basal autophagy, indicating that this pathway significantly contributes to sustained 
basal autophagic activity in BRAF mutated melanoma cells. These data were also confirmed in 
A2058 and SK-Mel-5 cell lines (Supplementary Figure S2A). To further support these observations, 
we also inhibited the activity of JNK by transient overexpression of a JNK dominant negative 
(Flag-JNK-DN) into A375 and A2058 cells. As shown in figure 5E and Supplementary Figure S2B, 
expression of JNK-DN clearly resulted in the inhibition of basal autophagy, as evidenced by 
reduced LC3 conversion compared to LC3-II expression in control vector transduced cells (E.V.).  
The known link between JNK and autophagy resides in the ability of active JNK to phosphorylate 
the inhibitory partners of Beclin 1, Bcl-XL and Bcl-2. Phosphorylated Bcl-XL and Bcl-2 are thus 
released by Beclin 1 enabling its subsequent ability to stimulate the autophagic process 37,38. To 
verify the involvement of Bcl-XL in our model, we immunoprecipitated a Flag-Beclin 1 
recombinant protein ectopically expressed in both GFP and BRAFV600E expressing SK-Mel-110 
cells, and analysed the presence of Bcl-XL by western blotting. As shown in figure 5F, the 
interaction between Beclin 1 and Bcl-XL was abrogated in BRAFV600E cells. On the other hand, to 
verify the activity of activated JNK on Bcl-2, we over-expressed wild type or a mutated (T69A 
S70A S87A) Bcl-2 protein 39 in A375 cells and analysed LC3 conversion in presence or absence of 
bafilomycin, in a time-course experiment. As reported in figure 5G, the presence of mutant Bcl-2 in 
which the phosphorylation sites have been mutated inhibited basal autophagy in A375 cells, 
compared to Bcl-2 wt expression. 
Taken together these data indicate BRAFV600E-induced ER stress-mediated constitutive activation of 
JNK results in the abrogation of Beclin 1/Bcl-XL and Beclin 1/Bcl-2 inhibitory interactions leading 
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to constitutive induction of autophagy, while does not affect the Beclin 1/Mcl-1 inhibitory bond, 
which is not regulated by phosphorylation of Mcl-1 (Fig 5F). 
 
ER stress-mediated TRB3 induction contributes to basal autophagy induction 
Our comparative analysis between wt and BRAF mutated melanoma cells, also evidenced an altered 
expression of an additional factor linking ER stress and autophagy, the mammalian homolog of 
Drosophila tribbles TRB3 40. qRT-PCR and western blotting revealed consistent up-regulation of 
TRB3 at both the mRNA and protein level in A375 compared to CHL-1 cells (Fig 6A left and 6B 
upper panel, respectively). A similar result was obtained comparing TRB3 expression in GFP- and 
BRAFV600E-expressing SK-Mel-110 cells (Fig 6A right and 6B bottom panel), indicating that TRB3 
up-regulation directly correlates with the presence of mutant BRAF. Moreover, we also confirmed 
the increased expression of TRB3 in BRAFV600E compared to BRAF wt cells in an extended cohort 
of melanoma cell lines (Supplementary Figure S3). 
Since ER stress-induced upregulation of TRB3 induces autophagy and the inhibition of the 
Akt/mTORC1 axis 41, we investigated the contribution of TRB3 to BRAFV600E-induced basal 
autophagy. RNAi mediated knockdown of TRB3 was carried out in A375 (Fig 6C) and the effect on 
basal autophagy rate analysed in presence or absence of bafilomycin. Similarly to the effects of 
JNK modulation (Fig 4 & 5) results demonstrated knockdown of TRB3 inhibited BRAFV600E-
induced increases in basal autophagy (Figure 6D and 6E, upper and middle panels).  
Finally, to determine the effect of dual inhibition of JNK and TRB3 on oncogenic BRAF-enhanced 
basal autophagy, we analysed LC3 conversion (by both western blotting and immunofluorescence 
analysis) and p62 degradation in A375 cells in which the JNK or the TRB3 pathways were 
individually or collectively abrogated. The concomitant inactivation of both TRB3 and JNK 
pathways resulted in significant reduction of LC3 conversion (Fig 6F), LC3 puncta accumulation 
(Fig 6E) and p62 degradation (Fig 6G), indicating an additive contribution of both signalling 
pathways to oncogenic BRAF-induced ER Stress-mediated basal autophagy. 
11 
 
p38 activation contributes to BRAF-induced ER stress 
Published data demonstrate melanoma cells harbouring hyper-activating mutations in BRAF or 
NRAS display increased activation of the stress activated protein kinase (SAPK)-p38 42. Moreover, 
it has been also reported that active p38 in cancer cells is able to induce an ER-stress response to 
coordinate cell survival through the activation of PERK and IRE-143. 
To evaluate the potential role of p38-mediated induction of chronic ER stress in BRAF mutant 
melanoma cells, we first compared the expression of activated p38 (P-p38) in CHL-1 and A375 
cells, demonstrating increased P-p38 levels in BRAF mutated compared to BRAF wt cells (Fig 7 A, 
upper panel), also confirmed in our cohort of melanoma cell lines (Supplementary Figure S4 A and 
B). To unveil the impact of constitutively activated p38 on melanoma basal autophagy, we inhibited 
the activity of p38 by ectopic expression of a p38 dominant negative (p38-DN) into A375 cells prior 
to evaluating the effect on LC3 conversion by western blotting. As shown in Supplementary Figure 
S4C, the expression of p38-DN resulted in clear inhibition of basal autophagy in A375 cells. 
Secondly, we inhibited the kinase activity of p38 by treatment of BRAFV600E mutated A375 cells 
with 10 μM SB202190 for 6 or 8 h. As shown in figure 7, impairment of p38 activity resulted in: i) 
the inhibition of JNK phosphorylation (Fig 7A, bottom panel), ii) ER stress response attenuation 
(Fig 7B), and iii) a decrease in basal levels of autophagy (Fig 7C and Supplementary Figure S4D). 
Furthermore, we also inhibited the expression of p38 in A375 cells by using two specific shRNA 
oligos (shp38#320 and #472), which, as shown in figure 7D and Supplementary Figure S4 (E & F), 
resulted in the inhibition of p38 expression as well as decreased expression of ERdj5, ERp57, 
TRB3, JNK phosphorylation and the accumulation of p62. The inhibition of p38 expression was 
also carried out in SK-Mel-5 cells by shRNA, and resulted in both TRB3 expression attenuation and 
decreased JNK activation (Supplementary Figure S4G), confirming results obtained in A375 cells. 
Collectively, these data suggest p38 signalling contributes to the induction of a chronic ER stress 
status in BRAF mutated melanoma cells, resulting in an increase in basal autophagic activity. 
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Chemical chaperones sensitizes BRAFV600E melanoma cells to apoptosis induction 
Autophagy is primarily a pro-survival process that is up-regulated in advanced stages of 
melanoma3, particularly in those tumours harbouring hyper-activating mutations in BRAF, to 
sustain cell survival and counter act apoptotic signalling induced by chemotherapeutic agents 3,20,30.  
The contribution of chronic ER stress to increased basal autophagy in BRAF mutated melanoma 
cells prompted us to test whether inhibition of incurred ER stress by chemical chaperones would 
lead to a decrease in basal autophagy and the increased susceptibility to cell death induction. Since 
4-Phenylbutyric acid (4-PBA), has been shown to reduce ER stress both in vivo and in vitro 44 we 
exposed SK-Mel-110 cells expressing BRAFV600E to 4-PBA (3 mM) for 3 weeks and compared the 
expression of the ER stress markers ATF4, ERp57 and TRB3 in either treated or untreated cells. 4-
PBA treatment significantly decreased the expression of all markers, indicating the relief of ER 
stress imposed by BRAFV600E (Fig 7E). In addition 4-PBA consistently and significantly reduced 
basal autophagy in SK-Mel-110 BRAFV600E cells, as evidenced by the reduced conversion and 
accumulation of LC3, in presence of bafilomycin (Fig 7F). These findings therefore indicate 4-PBA 
alleviates chronic ER stress in BRAFV600E mutant melanoma cells, with consequent reduction in 
basal autophagic activity.  
To determine the effect of 4-PBA induced reduction of ER stress and basal autophagy on 
susceptibility to apoptosis induction, SK-Mel-110 BRAFV600E cells were subsequently treated in the 
presence of absence of a panel of pro-apoptotic drugs, able to activate different apoptotic pathways; 
thapsigargin (TG, 10 μg/ml), staurosporine (STS, 0,2 μM) and doxorubicine (DoxR, 10 μM) (Fig 
7G). Results revealed 4-PBA significantly increased the sensitivity of SK-Mel-110 BRAFV600E cells 
to drug-induced apoptosis by all agents tested, thus suggesting chronic ER stress imposed by 
oncogenic BRAF expression and the subsequent increase in basal autophagy represents a skilled 
pro-survival mechanism used by these cells to escape cell death induction. 
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Discussion 
It is now quite clear that both autophagy and ER stress play pivotal roles in cancer development and 
progression, as well as response to pharmacological therapeutic intervention 45. Although autophagy 
may represent a primary barrier to cellular transformation and the prevention of tumour 
development, paradoxically, both pathways promote pro-survival cell responses, allowing tumour 
growth and progression, and possibly conferring chemoresistance 22,46. Thus, targeting ER stress 
and/or autophagy may present considerable benefit for cancer therapy 47. However, such potential is 
complicated by the inter-connection of both processes, and the fact that both ER stress and 
autophagy are able to modulate each other and that their specific function is strictly dependent on 
both tumour type and stage progression 45. In cutaneous metastatic melanoma we have recently 
demonstrated the clinical potential of ER stress-induced apoptosis, with BRAF wt melanomas 
showing greater sensitivity, compared to tumours harbouring hyper-activating mutations in the 
BRAF protein kinase 32,33. Moreover, we have also shown (and confirmed in the present study) that 
BRAF mutation is associated with increased levels of basal autophagy20. Interestingly, ER stress-
induced apoptosis is reduced in melanoma cells harbouring oncogenic BRAF compared to the 
observed induction in BRAF wt melanoma cells, and in this context and in contrast to observations 
in BRAF mutant melanoma cells, we have also shown that autophagy inhibition significantly 
sensitizes BRAF wt melanoma cells to ER stress-mediated apoptosis 20. Based on established 
evidence that: i) melanoma development and progression is accompanied by the induction of ER 
stress 30, ii) BRAFV600E melanomas are characterized by increased rates in basal autophagy 
compared to BRAF wt malignancies 20 and that iii) ER stress and autophagy are strictly linked 26, 
we now show mutation of BRAF confers a chronic ER stress status responsible for increased basal 
autophagy in melanoma cells. Specifically, the presence of BRAFV600E increases the expression of 
typical ER stress markers, compatible with a chronic ER stress status, possibly accounting for 
reduced sensitivity to further ER stress stimulation. Importantly, the ectopic expression of 
BRAFV600E mutation not only induced a chronic ER stress status but was also responsible for 
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increased basal autophagy. Furthermore, hyperactivation of BRAF, due to mutation, is directly 
responsible for p38 activation and subsequent ER stress induction. Moreover, the 
IRE1/TRAF2/ASK1/JNK branch of the unfolded protein response together with the TRB3 axis are 
key to ER stress-mediated autophagy induction observed in BRAF mutated melanoma cells. While 
JNK mediates the phosphorylation of both Bcl-XL and Bcl-2, responsible for Beclin 1 release and 
autophagy induction, TRB3, in turn, mediates Akt/mTORC1 inhibition and, thus, autophagy 
induction. 
Collectively these data demonstrate that oncogenic mutations in BRAF impose a chronic ER stress 
status within melanoma cells, resulting in enhanced basal levels of autophagy and that the increased 
activity of these two pro-survival signalling mechanisms contributes to the notorious 
chemoresistance of such tumour (schematically represented in Fig 7H). Inhibiting ER stress in 
BRAF mutant melanomas may thus represent a novel and valuable therapeutic strategy through 
which to inhibit both pro-survival ER stress and autophagy, and re-sensitize these tumours to 
chemotherapeutic intervention. Perhaps this approach may also overcome the potential for tumour 
recurrence in patients treated with autophagy inhibitors given autophagy inhibition per se may drive 
secondary tumourigenesis. To our knowledge chemical chaperones are, at present, the only 
available molecules able to effectively reduce ER stress both in vitro and in vivo 44 and since in the 
present study prolonged 4-PBA treatment of BRAF mutated melanoma cells resulted in the reduced 
expression of both markers of ER stress and basal autophagy as well as increased sensitivity to pro-
apoptotic drugs, the clinical use of chemical chaperones may thus harness ER stress and autophagy 
modulation for the therapeutic benefit of patients bearing BRAF V600E tumours. 
Recent studies by Ma and colleagues identified ER stress and autophagy induction as a mechanism 
mediating resistance to BRAF inhibitor therapy in patients bearing BRAFV600E mutant melanomas 
suggesting a direct link between these two pathways 34. Our data thus complement the studies of Ma 
and colleagues and provide additional novel molecular insight into how oncogenic BRAF leads to a 
chronic ER stress state and the promotion of basal autophagy. Moreover given observations of ER 
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chemical chaperone mediated resensitization of BRAFV600E melanoma cells to a panel of pro-
apoptotic drugs, able to activate different apoptotic pathways, the use of drugs able to harness ER 
stress or, alternatively, to target the molecular pathways linking BRAFV600E-induced ER stress and 
basal autophagy (such as the IRE1/TRAF2/ASK1/JNK and the TRB3 axes) for the clinical benefit 
of such tumours is warranted. Observations demonstrating chloroquine/hydroxychloroquine can 
reduce tumour immunogenicity 48, and accelerate tumour formation 49, have questioned the benefit 
of autophagy inhibition in cancer therapy, and hence our novel proposed therapeutic approaches 
(ER stress buffering or JNK and TRB3 axes targeting) may also increase the sensitivity of BRAF 
mutant melanomas to clinical BRAF inhibition. 
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Materials and Methods 
 
Cell culture and treatments 
All cell lines were cultured in DMEM (Sigma-Aldrich) except for A2058 that were cultured in 
RPMI (Sigma-Aldrich). Cell culture medium was supplemented with 10% foetal bovine serum 
(FBS, Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 1% penicillin/streptomycin solution 
(Sigma-Aldrich) at 37°C under 5% CO2, except medium. Primary melanocytes have been 
previously described 10. Cells were treated with thapsigargin (Sigma-Aldrich) at a final 
concentration of 10 μg/ml, staurosporine (Sigma-Aldrich), 2 μM, doxorubicine (Sigma-Aldrich), 10 
μM, Bafilomycin A (Sigma-Aldrich), 5 nM, 4-PBA (Sigma-Aldrich), 3 mM, SP600125 (Sigma-
Aldrich), or 10 μM, SB202190 (Sigma-Aldrich) . All agents were added in DMSO or methanol with 
an equal volume of vehicle used to treat control cells (0.1-0.5% DMSO or Methanol).  
 
Retroviral generation and Infection  
15 g of retroviral vectors were co-transfected with 5g of expression plasmid for the vesicular 
stomatitis virus G protein into the 293 cell line gp/bsr using  calcium phosphate50 48 h later, 
supernatant containing retroviral particles was recovered and supplemented with polybrene 
(4mg/ml). Cells were infected by incubation with retroviral containing supernatant for 6–8 h as 
previously described 50. 
 
Lentiviral generation and infection 
10 μg of lentiviral vectors (shRNA-pLKO) were co-transfected with 2,5 μg of an expression 
plasmid for the vesicular stomatitis virus G protein and psPAX2 plasmid, containing gag, pol and 
rev genes, into the  293T packaging cell line using calcium phosphate as outlined above. 48 h later, 
the supernatant containing the lentiviral particles was recovered and supplemented with polybrene 
(4 μg/ml). Cells were infected by incubation with lentiviral containing supernatant for 6–8 h. 
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Cell transfection 
Expression vectors for BRAFV600E mutant12, GFP or pcDNA4 (Invitrogen), wt/mutant Bcl-2 39, 
JNK-DN 51 and p38-DN 52 (Addgene plasmids 8768, 13340, 13846, 20356, respectively) vectors 
were transiently transfected using lipofectamine LTX, accordingly to manufacturer’s 
recommendations. 
 
PCR for XBP-1 splicing 
The human XBP-1 sequence was amplified by PCR using the primer pair 
AAACAGAGTAGCAGCTCAGACTGC and CCTTCTGGGTAGACCTCTGGGAG as previously 
described 33. 
 
qRT-PCR 
RNA was extracted by using Trizol reagent (Invitrogen) as indicated by the supplier. cDNA 
synthesis was generated using a reverse transcription kit (Promega, Madison, WI, USA) according 
to the manufacturer’s recommendations. Quantitative PCR reactions were performed with the 
Rotor-Gene 6000 (Corbett Research Ltd) thermocycler. Primer sets for all amplicons were designed 
using the Primer-Express 1.0 software system (Roche): 
L34 forward: 5’-GTCCCGAACCCCTGGTAATAGA-3’ 
L34 reverse: 5’-GGCCCTGCTGACATGTTTCTT-3’ 
ERp57 forward: 5’-TGTGGCATCACGCAGTTTCA-3’ 
ERp57 reverse: 5’-GGGAAGTTAAAGGGCCACACC-3’ 
ATF4 forward: 5’-GTGGCCAAGCACTTCAAACC-3’ 
ATF4 reverse: 5’-CCCGGAGAAGGCATCCTC-3’ 
ERdj5 forward: 5’-TCATGTTACCACGCTTGGACC-3’ 
ERdj5 reverse: 5’-GTAAAGCTCGACATGGTGGACAC-3’ 
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Xbp-I (spliced) forward: 5’-GAATGAAGTGAGGCCAGTG-3’ 
Xbp-I (spliced) reverse: 5’-GAGTCAATACCGCCAGAATC-3’ 
IRE1 forward: 5’-GAGACCCTGCGCTATCTGACC-3’ 
IRE1 reverse: 5’-CAGAGTGGCGTCAGCTTG-3’ 
TRB3 forward: 5’-TCAAGCTGTGTCGCTTTGTCTTCG-3’ 
TRB3 reverse: 5’-TGCTTGTCCCACAGGGAATCATCT-3’ 
L34 mRNA level was used as an internal control and results were expressed as previously described 
50. 
 
Western blotting 
Total proteins were extracted from cells using the Cell Lytic buffer (Sigma-Aldrich) following 
addition of protease inhibitors and resolved by electrophoresis through NuPAGE Bis-Tris gel 
(Invitrogen) and electroblotted onto nitrocellulose (Protran) membrane. Blots were incubated with 
indicated primary antibodies in 5% non-fat dry milk in PBS plus 0.1% Tween20 overnight at 4°C. 
Primary antibodies were: anti-Beclin1 (1:500; Becton-Dickinson); anti-Gapdh (1:106;Calbiochem); 
anti-Flag (1:3000; Sigma-Aldrich), BRAF (1:500), CLX (1:500), TRAF2 (1:300) (Santa Cruz 
Biotechnology); LC3 (1:2000), ERK (1:2000), P-ERK (1:500), eIF2 (1:1000), P-eIF2 (1:500), JNK 
(1:1000), P-JNK (1:500), p38 (1:500), P-p38 (1:500) (Cell Signaling Technology); ERp57 (1:5000, 
Stressgen), Bcl-XL (1:300; Enzo Life Sciences), Bcl-2 (1:500; DAKO). Detection was achieved 
using horseradish peroxidase-conjugate secondary antibody (1:5000; Jackson ImmunoResearch) 
and visualized with ECL plus (Amersham Biosciences). 
 
Velocity sedimentation by sucrose gradient 
Cells were suspended in buffer containing 0.25 M sucrose, 10 mM Hepes, and 1 mM EDTA  and 
protease cocktail inhibitors and homogenized (Sigma-Aldrich) by 100 strokes in a dounce potter 
homogenizer and centrifuged for 10 min at 600g to obtain a post-nuclear supernatant. The post-
19 
nuclear supernatant was re-centrifuged for 15 min at 11,000g to obtain a post-mitochondrial 
supernatant. The post-mitochondrial supernatant was layered onto a discontinuous four-step 
gradient consisting of 2 ml each of 2.0 M, 1.3 M, 1.0 M, and 0.6 M sucrose in 10 mM Hepes. 
Centrifugation was performed using a rotor (SW41 Ti; Beckman Coulter) at 27,000 g for 18 h, and 
0.4-ml fractions were manually collected and checked for density. 
 
IP assay 
Cells were suspended in lyses buffer (10 mM Tris-HCl, pH 8.0, 0.5% NP40,) plus protease and 
phosphatase inhibitors (protease inhibitor cocktail plus 1 mM sodium fluoride, 1 mM sodium 
orthovanadate, and 1 mM sodium molibdate; Sigma-Aldrich). 1–3 mg lysates was incubated at 4°C 
for 30 min. After a centrifugation at 4°C for 10 min at 13,000g to remove insoluble debris, equal 
amounts of protein were incubated with 20 µl monoclonal anti-Flag antibody conjugated with 
protein A agarose beads (Takara and Sigma-Aldrich, respectively) with rotation at 4°C for 4 h 
followed by 60-min incubation with 30 µl protein A–Sepharose beads (Roche). The beads were 
collected by centrifugation and washed four times with lyses buffer. Proteins bound to the beads 
were eluted with 30 µl FLAG-peptide (200 ng/l, Sigma-Aldrich) with rotation at 4°C for 1 h 
followed by a centrifugation at 4°C for 10 min at 13,000g to remove beads. A 2x SDS-PAGE 
sample buffer was added and samples were boiled at 95°C for 10 min. WB analyses were 
performed as described above. 
 
Apoptosis analysis 
Flow cytometry of propidium iodide-stained cells was used to estimate the level of cell death or 
apoptosis by measuring the percentage of cells in the sub-G1 fraction 33. 
 
Confocal microscopy 
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Cells were grown on coverslips and fixed with 4% PFA in PBS followed by permeabilization with 
0.1% Triton X-100 in PBS. p62 primary antibody (1:500; MBL) was incubated for 1 h at RT and 
visualized by means of AlexaFluor-488 (1:300, Invitrogen). Coverslips were mounted in antifade 
(SlowFade; Invitrogen) and examined under a confocal microscope (TCS SP2; Leica) equipped 
with a 63x 1.40–0.60 NA HCX Plan Apo oil BL objective at RT. 
 
Autophagy assay 
Cells infected with a retroviral vector encoding p62-GFP were seeded at a concentration of 25 x 104 
cells/well in 6-well plates and treated as indicated. Cells were fixed in 4% PFA and fluorescence 
analysed by FACS analysis (FacsScan, Becton-Dickinson).  
For immunodetection of p62 puncta, cells were grown on coverslips and fixed with 4% PFA in 
PBS, washed three times, and incubated with anti-p62 antibody, as described above, prior to 
analysis confocal microscopy. Results were recorded as percentage of p62–positive cells with p62 
punctate as previously described 53. A minimum of 50–100 cells per sample was counted for 
triplicate samples per condition per experiment. 
 
Densitometric analysis 
In order to measure protein expression levels, intensities of specific bands, corresponding to the 
proteins of interest are measured using Gel Doc 2000 and QuantyOne software (BioRad). Briefly, 
blots were acquired using the Gel Doc 2000 apparatus; images were imported into the QuantyOne 
software; contrast was adjusted such that the bands were clearly visible on the blot image; area 
around each band was selected; background intensity was subtracted from the blot image; bands 
were then selected by drawing a tight boundary around them; intensities of the selected bands was 
exported in excel format which was used to perform further analysis; statistical analysis (t-test) was 
performed using Prism 5 software (GraphPad). 
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Statistical analysis 
Unless indicated otherwise, all data are presented as the means ± SD of the mean, and statistical 
differences were evaluated by two-tailed Student’s t-tests. For all analyses, we considered p<0.05 to 
be statistically significant.  
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Figure Legend 
 
Figure 1. Enhanced basal autophagy and less apoptotic responsiveness of BRAFV600E 
melanoma cells. BRAF wt (CHL-1) and BRAFV600E (A375) melanoma cells were exposed 3 and 6 
h (A) to bafilomycin A (Baf) and basal autophagy was evaluated by monitoring both the LC3 
conversion by western blotting analysis (A; Gapdh was used as loading control) and p62 
accumulation by immunofluorescence (B; bar = 10m). Basal autophagy was also evaluated in a 
panel of BRAFWT or BRAFV600E melanoma cell lines, in presence or absence of Baf (4h), by 
monitoring LC3 conversion by western blotting analysis (C, left panels; Gapdh was used as loading 
control). Densitometric analysis of LC3-II bands is shown in each cell lines, comparing treated to 
untreated cells (with Baf); mean ± s.d. of LC3-II bands in BRAFWT and BRAFV600E cell lines is also 
reported (C, right panel). Autophagic flux was quantitated in all melanoma cell lines stably 
expressing a p62-GFP recombinant protein, treated with Baf in a time-dependent manner, by 
cytofluorimetric analysis (D; n = 3). Apoptosis induction was evaluated by cytofluorimetric analysis 
of propidium iodide-stained CHL-1 and A375 cells exposed 24h to thapsigargin (TG, 10g/ml; E; n 
= 3; p = 0.004). 
 
Figure 2. BRAF induces a chronic ER stress status. (A) BRAF-mediated ER stress was 
evaluated in both BRAFWT and BRAFV600E melanoma cell lines by measuring the mRNA levels of 
ER stress markers ERdj5, ERp57, ATF4 and Xbp-1 (spliced, mature form) by qRT-PCR (n = 3). 
BRAFV600E and GFP were transduced in BRAF wt SK-Mell-110 melanoma cells. BRAF and P-
ERK1/2 (ERK1/2 was used as loading control) protein levels were evaluated by western blotting 
analysis (C). ER stress status was monitored in GFP or BRAFV600E expressing cells comparing: (B) 
mRNA levels of ERp57, ATF4, ERdj5 and Xbp-1 (spliced, mature form) by qRT-PCR (n = 3); (D) 
protein level of Calnexin (CLX), ERp57 and eIF2a-P (eIF2a was used as loading control) by 
western blotting analysis; and (E) Xbp-1 mRNA splicing by RT-PCR. 
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Figure 3. BRAFV600E expression and basal autophagy. BRAFV600E and GFP or empty vector (E. 
V.) were transduced in BRAF wt SK-Mell-110 melanoma cells. Cell were incubated with 
bafilomycin A as indicated and basal autophagy was evaluated by both confocal analysis of p62 
puncta (A; bar = 10m) or LC3 conversion by western blotting (B; Gapdh was used as loading 
control). 
 
Figure 4. Autophagy modulation by the IRE1/TRAF2/JNK axis. JNK activation (P-JNK) was 
evaluated in primary melanocytes and in a panel of BRAFWT or BRAFV600E melanoma cell lines 
(A), or in SK-Mell-110 expressing GFP or BRAFV600E (C) cells by western blotting analysis (JNK 
was used as loading control). The recruitment of TRAF2 by activated IRE1 on ER was monitored 
by western blotting analysis of subcellular fractions from CHL-1 and A375 (B) or SK-Mell-110 
expressing GFP or BRAFV600E (D) cells, by using specific anti-TRAF2 and anti-CLX antibodies; 
arrows have been used to highlight the different distribution of TRAF2 onto ER membranes, 
between compared cell lines. (E) A375 cells were infected with indicated shIRE1 or shCtrl carrying 
lentiviruses and IRE1 levels were evaluated by qRT-PCR (right panel; p = 0.0005; n = 3); P-JNK 
was evaluated by western blotting analysis (JNK was used as loading control; upper panel) and LC3 
conversion was monitored by western blotting analysis in presence or absence of bafilomycin (Baf, 
3h; Gapdh was used as loading control; bottom panel). 
 
Figure 5. JNK and basal autophagy. A375 cells were exposed to SP600125 and JNK activation 
(P-JNK) was evaluated by western blotting analysis (A; JNK was used as loading control). A375 
cells expressing a p62-GFP recombinant protein were treated or untreated with bafilomycin A (Baf, 
4h) and SP600125 (6h) alone or in combination, and the occurrence of autophagy was analysed by 
measuring p62-GFP levels by citofluorimetric analysis (B; n = 3), LC3 conversion by western 
31 
blotting analysis (C; Gapdh was used as loading control), and by evaluating the presence of p62-
GFP cytosolic puncta by confocal analysis (D; bar = 10m).  
A Flag-tagged JNK dominant negative (JNK-DN) was ectopically expressed in A375 cells by 
transient transfection and expression levels of JNK-DN protein and LC3 conversion and 
accumulation were evaluated in presence or absence of Baf, by western blotting (E). GFP or 
BRAFV600E expressing SK-Mel-110 cells were transiently transfected with expression plasmids 
encoding Flag-tagged Beclin 1 and protein extracts were subjected to IP using an anti-Flag 
antibody. Purified complexes were analysed together with the corresponding total extracts by WB 
using anti-Flag (F, top), anti-Bcl-XL (F, middle) and anti-Mcl-1 (bottom) antibodies. A375 cells 
were transiently transfected with expression plasmids encoding wild type or a T69A/S70A/S87A 
mutant Bcl-2. Cells were treated or untreated with bafilomycin, as indicated, and total Bcl-2 protein 
expression together with LC3 conversion were evaluated by western blotting analysis (G; Gapdh 
was used as loading control). 
 
Figure 6. Modulation of TRB3 expression by BRAF. TRB3 expression was evaluated in CHL-1, 
A375 and SK-Mel-110 expressing GFP or BRAFV600E cells, by qRT-PCR (A) and western blotting 
(B). A375 cells were transiently transfected with specific siRNA oligos and TRB3 down-regulation 
was evaluated by both qRT-PCR and western blotting (C). Cells were then treated or untreated with 
bafilomycin and LC3 conversion or p62 puncta accumulation were evaluated by western blotting 
(D; Gapdh was used as loading control) or confocal (E) analysis, respectively. Cells were also 
treated in presence or absence of both bafilomycin and SP600125 as indicated, and autophagic rate 
was evaluated by measuring the LC3 conversion by western blotting (F; Gapdh was used as loading 
control) or by p62 puncta accumulation by confocal microscopy (E; bar = 10 m). A375 expressing 
a p62-GFP recombinant protein were transiently transfected with specific siRNA oligos (siCtrl or 
siTRB3), treated as in B and autophagic flux was evaluated by measuring the levels of p62-GFP by 
flow cytometry (G; *p = 0.0002; **p = 0.003; n = 3). 
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Figure 7.  p38 activation and ER stress induction in BRAF mutated cells. p38 activation (P-
p38) was evaluated by western blotting analysis in both CHL-1 and A375 (A, upper panel; p38 was 
used as loading control). A375 cells were treated or untreated with SB202190 inhibitor as indicated 
and JNK activation (P-JNK), Calnexin (CLX) and ERp57 expression were evaluated by western 
blotting analysis (A, bottom panel, and B; JNK or Gapdh were used as loading control). LC3 
conversion was evaluated in A375 exposed to SB202190 (8h) in presence or absence of bafilomycin 
A by western blotting analysis (C; Gapdh was used as loading control). A375 were transiently 
transfected with specific siRNA oligos and p38, P-JNK, TRB3 and p62 protein levels were 
evaluated by western blotting analysis (D; Gapdh was used as loading control). The expression of 
TRB3 and ER stress markers (ATF4, ERp57), and LC3 conversion were evaluated in SK-Mel-110 
BRAFV600E cells continuously exposed to 4-PBA (3 mM), by qRT-PCR or western blotting (E and 
F; Gapdh was used as loading control; *p = 0.012; **p = 0.025; ***p = 0.002; n = 3), in presence or 
absence of Bafilomycin A, as indicated. Apoptotic rates were compared in SK-Mel-110 BRAFV600E 
cells in presence or absence of 4-PBA, treated or untreated 24h with thapsigargin (TG), 
staurosporine (STS) or doxurubicine (DoxR), by cytofluorimetric analysis of PI-stained cells (G). 
Schematic representation of BRAF induced ER stress and basal autophagy modulation (H). 
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Supplementary Figure S1
TRAF2 relocalization onto ER membranes in BRAFV600E melanoma cell lines. Recruitment of TRAF2 
by activated IRE1 on ER was monitored by western blotting analysis of subcellular fractions from BRAF wild-
type (MeWo) or BRAF V600E (A2058 and SK-Mel-5) melanoma cell lines, by using specific anti-TRAF2 
and anti-CLX antibodies; fractions showing different distribution of TRAF2 onto ER membranes in compared
cell lines have been highlight.
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Supplementary Figure S2
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Oncogenic BRAF-dependent JNK activation and basal autophagy modulation. (A) A2058 and SK-Mel-5 cells
were exposed to SP600125 and JNK activation (P-JNK) was evaluated in presence or absence of Baf (Gapdh was
used as loading control); (B) A Flag-tagged JNK dominant negative (JNK-DN) was ectopically expressed in A2058
cells by transient transfection and expression levels of JNK-DN and p62 protein, and LC3 conversion and
accumulation were evaluated in presence or absence of Baf, by western blotting analysis (Gapdh was used as loading
control).
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Supplementary Figure S3
TRB3 expression in melanoma cell. The expression of TRB3 has been evaluated in an extended panel of 
human skin melanoma cell lines carrying BRAF wt or V600E oncogenic mutation, by qRT-PCR.
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Oncogenic BRAF-induced p38-mediated ER stress and enhanced basal autophagy. (A) Activation of p38 (P-p38)
was evaluated in both BRAF wt and V600E melanoma cell lines by western blotting analysis. A densitometric analysis
has been carried out, using total p38 as internal control and values have been highlighted; a plot with mean ± s.d. of 
P-p38 levels of all BRAF wild-type and mutated melanoma cells is shown in B. (C) A375 cells were transiently
transfected with a p38 dominant negative (p38-DN) or an empty vector (E.V.) and p38 expression or LC3 conversion 
was evaluated by western blotting, in presence or absence of Baf (4h) as indicated (Gapdh was used as loading control).
(D) Autophagic flux was also quantitated in all melanoma cell lines expressing a p62-GFP recombinant protein, in
presence or absence of SB202190 (8h) alone or in combination with Baf (6h), by cytofluorimetric analysis. A375 cells
were infected with indicated shp38 or shCtrl carrying lentiviruses and ERp57, ERdj5 (E) or TRB3 (F) expression levels
were evaluated by qRT-PCR. (G) p38 expression was inhibited in SK-Mel-5 cells using shRNA (lentiviral infection) 
and p38 (right panel) and TRB3 (middle panel) expression was evaluated by qRT-PCR, and P-JNK level was evaluated 
by WB (left panel).
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Supplementary Table 1 
Human skin melanoma cell line genetic alterations. 
Name BRAF status Mutation 
A2058 mutant V600E 
A375 mutant V600E 
CHL-1 wild type / 
G-361 mutant V600E 
MeWo wild type / 
SK-Mel-5 mutant V600E 
SK-Mel-28 mutant V600E 
SK-Mel-110 wild type / 
 
